SCHEMBL3247547

SCHEMBL3247547

CCC(C(=O)O)N(c1ccc(Cl)cc1Cc1ccccc1Cl)S(=O)(=O)c1cccc(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
FLT1 P17948 1/20 0.42
FLT4 P35916 1/20 0.42
KDR P35968 1/20 0.42
SLC16A3 O15427 2/20 0.40
SLC16A1 P53985 2/20 0.40
PSEN1 P49768 3/20 0.38
PSEN2 P49810 3/20 0.38
APH1B Q8WW43 3/20 0.38
NCSTN Q92542 3/20 0.38
APH1A Q96BI3 3/20 0.38
PSENEN Q9NZ42 3/20 0.38
TAS2R14 Q9NYV8 2/20 0.38
PGR P06401 2/20 0.38
OXTR P30559 1/20 0.37
AVPR1A P37288 1/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3255563 0.81 KEAP1 (0.53) KEAP1NFE2L2FLT1FLT4KDR
SCHEMBL3243810 0.81 KEAP1 (0.51) KEAP1NFE2L2FLT1FLT4KDR
SCHEMBL3247610 0.73 KEAP1 (0.52) KEAP1NFE2L2MEN1KMT2AHPGD
SCHEMBL3253720 0.72 KEAP1 (0.62) KEAP1NFE2L2
SCHEMBL3247458 0.70 KEAP1 (0.58) KEAP1NFE2L2FLT1FLT4KDR
SCHEMBL4866253 0.70 PTGER1 (0.48) KEAP1NFE2L2MAPTCHRM5
SCHEMBL3257030 0.70 MAPK1 (0.52) FLT1FLT4KDRMEN1LMNA
SCHEMBL4867374 0.69 KEAP1 (0.43) KEAP1NFE2L2MEN1MAPTKMT2A
SCHEMBL3247753 0.69 PKM (0.57) KEAP1NFE2L2OXTRHPGD
SCHEMBL3249159 0.69 KEAP1 (0.48) KEAP1NFE2L2OXTRMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
EP-1776347-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-04-25 EP disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 KEAP1 3317/4885NFE2L2 2700/4885FLT1 3361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.